Prolonged Survival on PARP Inhibitor Therapy In a Patient With Stage IV Non-small Cell Lung Cancer: A Case Report

Authors

  • Ana Lucía González Herrera
  • Mustafa Al Gburi MD
  • Ahmed Ayad MD
  • Julio Peguero MD

Abstract

A BRCA1 mutation has been identified in a 56-year old female with adenocarcinoma of the lung. Following partial response with Nivolumab therapy, the patient started maintenance therapy with Olaparib, a PolyADP-ribose Polymerase (PARP) inhibitor showing sustained progression free response that is still ongoing.

Downloads

Published

2019-03-21

How to Cite

Herrera, A. L. G., MD, M. A. G., MD, A. A., & MD, J. P. (2019). Prolonged Survival on PARP Inhibitor Therapy In a Patient With Stage IV Non-small Cell Lung Cancer: A Case Report. Archives of Clinical and Medical Case Reports, 3(2), 59–61. Retrieved from https://fortunejournals.org/ojs/index.php/acmcr/article/view/22121

Issue

Vol. 3 No. 2 (2019): Volume 3, Issue 2

Section

Articles